貨號(hào)：GS40478

Nivolumab is a fully human IgG4 monoclonal antibody that functions as a programmed cell death?1 (PD?1) immune checkpoint inhibitor. It binds with high affinity to the PD?1 receptor on T cells, blocking its interaction with its ligands PD?L1 and PD?L2. This blockade reverses PD?1?mediated immunosuppression, restoring T?cell activation and enhancing anti?tumor immune responses. Nivolumab is approved for a wide range of advanced solid tumors and hematologic malignancies, including melanoma, non?small cell lung cancer (NSCLC), renal cell carcinoma (RCC), Hodgkin lymphoma, head and neck cancer, hepatocellular carcinoma (HCC), and others, both as monotherapy and in combination with other agents (e.g., ipilimumab). It is administered via intravenous infusion.